Study S001328

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01952145
Acronym: DUAL™ V
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 557
Start: 2013-09-20
Primary completion: 2014-11-04
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:insulin degludec/liraglutide; DRUG:insulin glargine
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2012-004413-14; OTHER:U1111-1135-1003

Registered primary outcomes

Change From Baseline in HbA1c (Glycosylated Haemoglobin) [Week 0, week 26]

Linked records (13)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010237	Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews	2025	Systematic review	PMID 39963952 DOI	cites ClinicalTrials.gov:NCT01952145; registry reference DERIVED:39963952
R0012514	Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes. Philis-Tsimikas A, Journal of diabetes science and technology	2024	Other trial	PMID 36710452 DOI	cites ClinicalTrials.gov:NCT01952145; registry reference DERIVED:36710452
R0014338	Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin. Meneghini L, Diabetic medicine : a journal of the British Diabetic Association	2020	Nonrandomized study	PMID 31705547 DOI	cites ClinicalTrials.gov:NCT01952145; registry reference DERIVED:31705547
R0018886	Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets. Cannon AJ, Journal of managed care & specialty pharmacy	2020	Randomized trial	PMID 31856636 DOI	cites ClinicalTrials.gov:NCT01952145
R0050381	Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial John B. Buse, Carolina Digital Repository (University of North Carolina at Chapel Hill)	2020	Randomized trial	DOI	cites ClinicalTrials.gov:NCT01952145
R0007584	EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Lingvay I, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists	2019	Randomized trial	PMID 30383495 DOI	registry reference RESULT:30383495
R0015446	Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. Lingvay I, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 28643425 DOI	cites ClinicalTrials.gov:NCT01952145; registry reference RESULT:28643425
R0053357	Lower Day-to-Day Fasting Self-Measured Plasma Glucose (SMPG) Variability with Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine 100 Units/mL (IGlar U100) Ildiko Lingvay, Diabetes	2018	Other	DOI	cites ClinicalTrials.gov:NCT01952145
R0012344	Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. Hunt B, Journal of medical economics	2017	Other trial	PMID 28294641 DOI	registry reference RESULT:28294641
R0015570	Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Norwood P, Diabetes, obesity & metabolism	2017	Other	PMID 28417535 DOI	registry reference RESULT:28417535
R0016941	Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system. Psota M, ClinicoEconomics and outcomes research : CEOR	2017	Other	PMID 29276398 DOI	registry reference RESULT:29276398
R0024244	Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. Hunt B, Advances in therapy	2017	Other trial	PMID 28281218 DOI	registry reference RESULT:28281218
R0021096	Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. Lingvay I, JAMA	2016	Randomized trial	PMID 26934259 DOI	cites ClinicalTrials.gov:NCT01952145; registry reference RESULT:26934259